[X]

Greenpharm – vaccine production in tobacco leaf

GreenPharm offers a new, scalable manufacturing technology that makes use of transient expression for rapid expression of product.

 

Contact Person

Funzani Libago

flibago@csir.co.za

Applications

Post-exposure prophylaxis against rabies

Intellectual Property

Safer – mammalian pathogen-free Greater efficacy Reliable supply – technology scalable to suit demand Cost effective

Technology Field

Biosciences

Business Opportunity

Seeking investment for pre-clinical and clinical trials

Technology Description

GreenPharm has developed a monoclonal antibody (mAb)-based post-exposure prophylaxis against rabies, which is an acute viral disease transmitted through the bite of rabid animals. The unique cocktail of two potent mAB’s, known as Rabivir™, will replace the current post-exposure treatment which uses human or equine rabies immune globulin. GreenPharm offers a new, scalable manufacturing technology that makes use of transient expression for rapid expression of product. This proprietary manufacturing platform will substantially lower the manufacturing cost and this is likely to allow RabiVir™ to be a better priced product for the combat of rabies in developing countries.

Benefits & Advantages

Safer – mammalian pathogen-free Greater efficacy Reliable supply – technology scalable to suit demand Cost effective

Inventors

Sonia Rech, Stoyan Stoychev, Tsepo Tsekoa,Therese Stark, Erek Chakauya, Rachel Chikwamba, Fanie Marais